1. Home
  2. JKS vs NTLA Comparison

JKS vs NTLA Comparison

Compare JKS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JinkoSolar Holding Company Limited (each representing 4)

JKS

JinkoSolar Holding Company Limited (each representing 4)

HOLD

Current Price

$24.02

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.95

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JKS
NTLA
Founded
2006
2014
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
JKS
NTLA
Price
$24.02
$14.95
Analyst Decision
Hold
Buy
Analyst Count
4
20
Target Price
$25.25
$20.45
AVG Volume (30 Days)
448.6K
2.9M
Earning Date
03-23-2026
05-07-2026
Dividend Yield
5.39%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$37.42
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$15.55
$6.80
52 Week High
$31.88
$28.24

Technical Indicators

Market Signals
Indicator
JKS
NTLA
Relative Strength Index (RSI) 47.03 63.09
Support Level $23.78 $10.44
Resistance Level $26.17 $15.51
Average True Range (ATR) 1.01 0.83
MACD -0.01 0.19
Stochastic Oscillator 41.69 90.70

Price Performance

Historical Comparison
JKS
NTLA

About JKS JinkoSolar Holding Company Limited (each representing 4)

JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: